Efficacy and Safety of TRC041266 in Patients With Heart Failure, LVEF ≥40%, Diastolic Dysfunction and Type 2 Diabetes Mellitus

Summary

This study will be conducted as a randomized, multi-centre, double-blind, parallel-group, placebo-controlled study in patients receiving SoC therapy. Eligible participants will be randomized in a ratio of 1:1 to receive either test product, TRC041266 1500 mg or matching placebo twice daily for 48 weeks

Timeline

Start

2021-06

Primary completion

2024-06

Completion

2024-06

Outcome

Outcome not reported

Stopped (Enrollment): “Study halted prematurely, prior to enrollment of first participant hence study withdrawn”

Drugs

Indications